Town Editor


North Penn — News

Teva Wants to Pay $500M Bond to Block Competitors in MS Drug Manufacture

North Penn TAP Staff

Sunday, April 20, 2014 • 8:58pm

Teva Pharmaceuticals told the U.S. Supreme Court it will pony up a $500 million bond to block competitors from manufacturing and marketing generic multiple sclerosis medications, according to Reuters.

Teva wants the Supreme Court to suspend a July 2013 decision by the U.S. Court of Appeals for the Federal Circuit "that invalidated some of its patents for the top-selling multiple sclerosis drug, Copaxone," according to the report.

The appeals court ruling gave the go-ahead for Novartis' Sandoz Inc. and Momenta Pharmaceuticals, and Mylan Inc. and Natco Pharma Inc. to develop generic MS drugs.

TAP into your town! Get Your Town's News In Your Inbox: Click here to sign up.